Unicycive Therapeutics (UNCY) Shares Outstanding (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Shares Outstanding (Entity) data on file, last reported at $25.2 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 110.75% year-over-year to $25.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.2 million (up 110.75% YoY) and the FY2025 annual result came in at $15.9 million, up 137.17% from the prior year.
• Shares Outstanding (Entity) rose to $25.2 million in Q1 2026, from $15.9 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $25.2 million in Q1 2026 to a low of $1.5 million in Q1 2022.
• A 5-year average of $7.5 million and a median of $3.8 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) grew 0.77% — and 2025, when it surged 223.87%.
• Tracing UNCY's Shares Outstanding (Entity) over 5 years: stood at $1.5 million in 2022, then surged by 61.11% to $2.5 million in 2023, then jumped by 172.97% to $6.7 million in 2024, then jumped by 137.17% to $15.9 million in 2025, then surged by 58.86% to $25.2 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $25.2 million (Q1 2026), $15.9 million (Q4 2025), and $20.9 million (Q3 2025), per Business Quant data.